Trial: 202105045

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy

Phase

II

Principal Investigator

Pusic, Iskra

Disease Site

Hodgkin Lymphoma; Leukemia, other; Lymphoid Leukemia; Multiple Myeloma; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov